41. Participant reflections from the program for evaluation of Ashkenazi Jewish Cancer heritability involving the BRCA genes

Abstract

One in 40 Ashkenazi Jewish individuals carries a BRCA1/2 mutation, which confers significantly increased risks for breast, ovarian, prostate and pancreatic cancer. Targeted cancer screening and surgical management can substantially reduce morbidity and mortality for carriers. The JScreen program conducted The Program for Evaluation of Ashkenazi Jewish Cancer Heritability Involving the BRCA Genes Study ('The PEACH BRCA Study') to test low-risk Ashkenazi Jewish individuals in the metro-Atlanta area for mutations in the BRCA genes using at-home, saliva-based testing.